2 Information about nivolumab with ipilimumab

2 Information about nivolumab with ipilimumab

Marketing authorisation indication

Nivolumab (Opdivo, Bristol-Myers Squibb) with ipilimumab (Yervoy, Bristol-Myers Squibb) has a marketing authorisation 'for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma'.

Dosage in the marketing authorisation

Nivolumab 3 mg/kg with ipilimumab 1 mg/kg by intravenous infusion every 3 weeks for 4 doses followed by nivolumab 480 mg every 4 weeks or 240 mg every 2 weeks (previously 3 mg/kg every 2 weeks).

Price

Nivolumab is available at a list price of £439 per 40 mg vial or £1,097 per 100 mg vial (excluding VAT; British national formulary online, accessed November 2018). Ipilimumab is available at a list price of £15,000 per 200 mg vial or £3,750 per 50 mg vial (excluding VAT; British national formulary online, accessed November 2018).

The company has commercial arrangements for nivolumab with ipilimumab. This makes nivolumab with ipilimumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)